↓ Skip to main content

Dove Medical Press

The clinical application of linagliptin in Asians

Overview of attention for article published in Therapeutics and Clinical Risk Management, September 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
3 X users
patent
25 patents

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
22 Mendeley
Title
The clinical application of linagliptin in Asians
Published in
Therapeutics and Clinical Risk Management, September 2015
DOI 10.2147/tcrm.s64402
Pubmed ID
Authors

Chu-qing Cao, Yu-fei Xiang, Zhi-guang Zhou

Abstract

Asia has a growing diabetic population. Linagliptin, a member of dipeptidyl peptidase-4 inhibitor class, is unique in its nonlinear pharmacokinetics with the characteristics of rapid attainment of steady state, little accumulation, predominantly nonrenal route of elimination, prolonged terminal half-life, and sustained inhibition of dipeptidyl peptidase-4 enzyme. No clinically relevant difference in pharmacokinetics was observed between Asians and non-Asians. The management of type 2 diabetes is increasingly challenging with the progression of disease, especially with the requirements of minimal hypoglycemia, weight gain, fluid retention, and other adverse effects. Linagliptin was efficacious and well-tolerated in Asian type 2 diabetes patients with or without renal or hepatic dysfunctions, comparable to that in Caucasians. This review will focus on the usage of linagliptin in clinical studies in Asians.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 23%
Other 3 14%
Student > Postgraduate 3 14%
Librarian 2 9%
Researcher 2 9%
Other 2 9%
Unknown 5 23%
Readers by discipline Count As %
Medicine and Dentistry 10 45%
Pharmacology, Toxicology and Pharmaceutical Science 4 18%
Computer Science 1 5%
Business, Management and Accounting 1 5%
Unknown 6 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2024.
All research outputs
#7,274,768
of 25,576,275 outputs
Outputs from Therapeutics and Clinical Risk Management
#367
of 1,324 outputs
Outputs of similar age
#78,213
of 277,197 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#16
of 62 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 1,324 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.7. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,197 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.